Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers

International Journal of Cancer. Journal International Du Cancer
Byonggu AnYoshitaka Sekido

Abstract

Aberrant DNA methylation is involved in colon carcinogenesis. Although the CpG island methylator phenotype (CIMP) is defined as a subset of colorectal cancers (CRCs) with remarkably high levels of DNA methylation, it is not known whether epigenetic processes are also involved in CIMP-negative tumors. We analyzed the DNA methylation profiles of 94 CRCs and their corresponding normal-appearing colonic mucosa with 11 different markers, including the five classical CIMP markers. The CIMP markers were frequently methylated in proximal CRCs (p < 0.01); however, RASSF1A methylation levels were significantly higher in distal CRCs, the majority of which are CIMP-negative (p < 0.05). Similarly, methylation levels of RASSF1A and SFRP1 in the normal-appearing mucosae of distal CRC cases were significantly higher than those in the proximal CRC cases (p < 0.05). They were also positively correlated with age (RASSF1A, p < 0.01; SFRP1, p < 0.01). Microarray-based genome-wide DNA methylation analysis of 18 CRCs revealed that 168 genes and 720 genes were preferentially methylated in CIMP-negative distal CRCs and CIMP-positive CRCs, respectively. Interestingly, more than half of the hypermethylated genes in CIMP-negative distal CRCs were also met...Continue Reading

References

Aug 11, 1994·Nucleic Acids Research·S J ClarkM Frommer
Oct 18, 1996·Cell·K W Kinzler, B Vogelstein
Mar 1, 1997·Current Biology : CB·S U KassA P Wolffe
Jan 8, 1998·International Journal of Cancer. Journal International Du Cancer·J BreivikG Gaudernack
Dec 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·M B EisenD Botstein
Feb 13, 1999·Nature Genetics·P A Jones, P W Laird
Jul 21, 1999·Proceedings of the National Academy of Sciences of the United States of America·M ToyotaJ P Issa
Jun 4, 2002·Nature Reviews. Genetics·Peter A Jones, Stephen B Baylin
Sep 7, 2002·International Journal of Cancer. Journal International Du Cancer·Barry Iacopetta
Feb 14, 2003·Lancet·Francisco Guarner, Juan-R Malagelada
Jun 5, 2003·Lancet·D J W Knight, K J Girling
Feb 20, 2004·Nucleic Acids Research·Allen S YangJean-Pierre J Issa
Aug 3, 2004·Nature Medicine·Bert Vogelstein, Kenneth W Kinzler
Dec 2, 2004·Nature Reviews. Cancer·Jean-Pierre Issa
Sep 7, 2005·Gastroenterology·Jean-Pierre J IssaMinoru Toyota
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shuji OginoCharles S Fuchs
Sep 22, 2005·Journal of the National Cancer Institute·Lanlan ShenJean-Pierre J Issa
Feb 24, 2006·Nature Reviews. Cancer·Stephen B Baylin, Joyce E Ohm
Mar 31, 2007·Journal of Biochemistry and Molecular Biology·Toshikazu Ushijima
Aug 11, 2007·The Journal of Molecular Diagnostics : JMD·Cynthia SpittleRobin H Edwards
Oct 17, 2007·Gut·William M Grady
Nov 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Lanlan ShenJean-Pierre J Issa
Mar 28, 2008·International Journal of Cancer. Journal International Du Cancer·Shuji OginoCharles S Fuchs
May 20, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Guoren DengYoung S Kim
Aug 30, 2008·PLoS Genetics·Yanis A BoumberJean-Pierre J Issa
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean-Pierre Issa
Nov 6, 2009·Cancer Research·Yasuhiro GotoYoshitaka Sekido

❮ Previous
Next ❯

Citations

Mar 7, 2013·Nature Structural & Molecular Biology·Yehudit Bergman, Howard Cedar
Apr 15, 2011·Journal of Biomedicine & Biotechnology·Lucia MiglioreFabio Coppedè
Jun 19, 2012·Clinical Epigenetics·Nakarin Kitkumthorn, Apiwat Mutirangura
Nov 8, 2011·Biochimica Et Biophysica Acta·Laura A E HughesManon van Engeland
Jun 27, 2012·International Journal of Cancer. Journal International Du Cancer·Maria Sofia FernandesRaquel Seruca
Jan 13, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·S VeganzonesE Díaz-Rubio
Aug 27, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Hassan AshktorabHassan Brim
Mar 1, 2018·Journal of Translational Medicine·Micaela FreitasCarmen Jerónimo
Jul 9, 2017·BMC Cancer·Kelly J GregorySallie S Schneider
May 6, 2020·Journal of Neuro-oncology·Atsushi NatsumeUNKNOWN and Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG)
Jun 13, 2015·Cancer Prevention Research·Norihisa IchimuraYutaka Kondo
Jan 24, 2014·Cancer Research·Deborah NejmanHoward Cedar
Jan 5, 2014·Cancer Research·Tomomitsu TaharaJean-Pierre J Issa
Mar 17, 2011·The American Journal of Pathology·Hai-Xing JuYutaka Kondo
Jul 29, 2010·Expert Reviews in Molecular Medicine·Yutaka Kondo, Jean-Pierre J Issa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
Lanlan ShenJean-Pierre J Issa
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Stefan de VogelManon van Engeland
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Anna M DahlinBethany Van Guelpen
Virchows Archiv : an International Journal of Pathology
Jung Ho KimGyeong Hoon Kang
© 2021 Meta ULC. All rights reserved